EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Poly(I:C) enhances vaccination-supported adoptive T-cell therapy associated with remodeling of the tumor immune microenvironment in sarcoma

Situo Deng, Daisuke Muraoka, Kiyoshi Yasui, Mitsuhiro Yoneda, Pengyu Miao, Chenxu Jiang, Huimin Sun, Xiangyue Meng, Kazunari Akiyoshi, Hiroaki Ikeda

Frontiers in Immunology · 16.11.2026 · 17

DOI: 10.3389/fimmu.2026.1925101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 16.11.2026. Verfasst von Situo Deng und 9 weiteren Autor:innen. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takara Bio.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy of adoptive cell therapy (ACT) in solid tumors is often constrained by an unfavorable tumor microenvironment. Poly(I:C)-mediated innate immune activation can enhance antitumor immunity; however, its impact on the sarcoma immune microenvironment during ACT remains unclear.

Methods

We evaluated the therapeutic and immune-modulatory effects of poly(I:C) in vaccine-augmented ACT in murine sarcoma models. Flow cytometry was used to assess tumor-infiltrating CD8 + T cells and myeloid populations, and intracellular cytokine staining was performed after ex vivo restimulation. Public bulk RNA-seq datasets from poly(I:C)-treated murine sarcoma and single-cell RNA-seq data from human sarcoma treated with radiotherapy with or without BO-112 were analyzed to identify treatment-associated immune programs. The clinical relevance of TLR3-associated immune activation was evaluated using the TCGA-SARC cohort.

Results

Poly(I:C) enhanced the efficacy of vaccination-supported ACT, inducing marked tumor control in antigen-positive CMS5a sarcoma and CT26/9m tumor models, with complete regression observed in a subset of tumor-bearing mice. This was associated with increased intratumoral accumulation of adoptively transferred CD8 + T cells, enhanced functional responsiveness of tumor-infiltrating CD8 + T cells, and substantial remodeling of Ly6C/MHCII-defined myeloid cell populations. Bulk transcriptomic analyses of poly(I:C)-treated murine sarcoma identified coordinated interferon-response, antigen-presentation, myeloid/APC, and cytotoxic immune programs, whereas single-cell analysis of human sarcoma identified treatment-associated remodeling of myeloid states and antigen-presentation programs. Higher TLR3 expression and TLR3-associated immune activation signatures were associated with favorable survival in TCGA-SARC.

Conclusions

Addition of poly(I:C) reshapes the sarcoma immune microenvironment, particularly in myeloid compartments, and enhances the efficacy of ACT against antigen-positive tumors. These findings support further investigation of poly(I:C)-based innate immune activation as a strategy to improve vaccination-supported ACT in solid tumors and suggest that myeloid remodeling associated with enhanced antigen-presentation capacity is linked to improved intratumoral CD8 + T-cell responses.

Förderung

  • Takara Bio

Zitieren

APA

Deng, S., Muraoka, D., Yasui, K., Yoneda, M., Miao, P., Jiang, C., Sun, H., Meng, X., Akiyoshi, K., & Ikeda, H. (2026). Poly(I:C) enhances vaccination-supported adoptive T-cell therapy associated with remodeling of the tumor immune microenvironment in sarcoma. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1925101

Vancouver

Deng S, Muraoka D, Yasui K, Yoneda M, Miao P, Jiang C, et al. Poly(I:C) enhances vaccination-supported adoptive T-cell therapy associated with remodeling of the tumor immune microenvironment in sarcoma. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1925101

BibTeX
@article{Deng2026,
  author = {Deng, Situo and Muraoka, Daisuke and Yasui, Kiyoshi and Yoneda, Mitsuhiro and Miao, Pengyu and Jiang, Chenxu and Sun, Huimin and Meng, Xiangyue and Akiyoshi, Kazunari and Ikeda, Hiroaki},
  title = {Poly(I:C) enhances vaccination-supported adoptive T-cell therapy associated with remodeling of the tumor immune microenvironment in sarcoma},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1925101}
}
Kostenlos starten →